S. Choo

K. Soo, S. Choo, C. Chua, 2017, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial

J. Bruix, A. El-Khoueiry, B. Sangro, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.

M. Kudo, J. Furuse, G. Abou-Alfa, 2021, The Lancet. Oncology.

Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.

Robert S Warren, E. Nakakura, S. Choo, 2008, Endocrine-related cancer.

Systematic review of the outcomes of surgical resection for intermediate and advanced Barcelona Clinic Liver Cancer stage hepatocellular carcinoma: A critical appraisal of the evidence

S. Choo, B. Goh, W. Lye, 2018, World journal of hepatology.

Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial

K. Soo, C. Thng, P. Chow, 2016, BMC Cancer.

Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition

Jia Qi Lim, A. Jeyasekharan, L. Molinero, 2021, Gut.

Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers

S. Choo, Valerie Chew, D. Tai, 2019, Cancers.

The fibroblast growth factor receptor pathway in hepatocellular carcinoma

S. Choo, J. Lee, 2018, Hepatoma Research.

Identification of Serum Monocyte Chemoattractant Protein-1 and Prolactin as Potential Tumor Markers in Hepatocellular Carcinoma

S. Choo, Chee‐Kiat Tan, A. Utama, 2013, PloS one.

Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.

Jia Qi Lim, Hong Kai Lee, F. Ginhoux, 2021, Immunity.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with renal cell carcinoma

G. Bhattacharyya, S. Choo, R. Kanesvaran, 2021, ESMO open.

Liver fibrosis and CD206+ macrophage accumulation are suppressed by anti-GM-CSF therapy

F. Ginhoux, E. Newell, S. Choo, 2019, JHEP reports.

Potentially Functional SNPs (pfSNPs) as Novel Genomic Predictors of 5-FU Response in Metastatic Colorectal Cancer Patients

Y. Teo, S. Choo, Xu Wang, 2014, PloS one.

Patterns of somatic structural variation in human cancer genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.

Bin Tean Teh, Hiromi Nakamura, Chern Han Yong, 2017, Cancer discovery.

Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.

M. Kudo, Chiun Hsu, S. Choo, 2020, Journal of hepatology.

Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond

S. Choo, C. Yip, Valerie Chew, 2020, Frontiers in Immunology.

Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.

Jia Qi Lim, Hong Kai Lee, S. Choo, 2022, Journal of hepatology.

Metastatic gastric cancer: Does the site of metastasis make a difference?

K. Soo, S. Choo, C. Chua, 2018, Asia-Pacific journal of clinical oncology.

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

Gefitinib in Combination with Gemcitabine and Carboplatin in Never Smokers with Non-small Cell Lung Carcinoma: A Retrospective Analysis

S. Choo, E. Tan, W. Lim, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

H. Huynh, K. Soo, H. Koong, 2010, Journal of hepatology.

Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis.

M. Kudo, T. Yau, Chiun Hsu, 2019, Journal of hepatology.

The evolving landscape of therapeutic drug development for hepatocellular carcinoma.

S. Choo, I. Tan, D. Chong, 2013, Contemporary clinical trials.

Hypoglycaemia in a 63-Year-Old Female with a Large, Recurrent, Metastatic Gastrointestinal Stromal Tumour (GIST)

S. Choo, G. Tan, M. Teo, 2011, Journal of gastrointestinal cancer.

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma.

P. Philip, D. Porter, E. Van Cutsem, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.

M. Kudo, A. El-Khoueiry, B. Sangro, 2018 .

Gastrointestinal stromal tumour in the elderly.

S. Choo, M. Tan, D. Poon, 2009, Critical reviews in oncology/hematology.

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma

B. Au, J. Connolly, P. Chow, 2020, Journal for ImmunoTherapy of Cancer.

What is the value of third‐line chemotherapy in advanced gastroesophageal cancer? A 5‐year retrospective analysis at a single center

S. Choo, C. Chua, I. Tan, 2019, Asia-Pacific journal of clinical oncology.

Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma

S. Choo, J. Allen, B. Goh, 2014, Hepatology International.

Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO.

Y. Yen, G. Bhattacharyya, S. Choo, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.

V. Gebski, K. Soo, C. Thng, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

H. Huynh, K. Soo, H. Koong, 2009, Journal of cellular and molecular medicine.

A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements

M. Kudo, S. Choo, S. Ye, 2020, Liver Cancer.

"And what other medications are you taking?".

R. Kelley, S. Choo, A. Venook, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma.

S. Choo, S. Hee, S. Ong, 2008, Annals of the Academy of Medicine, Singapore.

Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group.

R. Bociek, F. Cavalli, S. Lade, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Nicolas Stransky, V. Mazzaferro, J. Llovet, 2019, Cancer discovery.

Real-Time Tumor Gene Expression Profiling to Direct Gastric Cancer Chemotherapy: Proof-of-Concept “3G” Trial

S. Choo, I. Tan, P. Tan, 2018, Clinical Cancer Research.

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma

V. Mazzaferro, M. Teufel, J. Llovet, 2018, Clinical Cancer Research.

Comparison of hepatocellular carcinoma in Eastern versus Western populations

A. Zhu, S. Choo, B. Goh, 2016, Cancer.

Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma

S. Choo, T. Lim, C. Chan, 2019, Front. Immunol..

A phase 2 study of BGJ398 in patients (pts) with advanced or metastatic FGFR-altered cholangiocarcinoma (CCA) who failed or are intolerant to platinum-based chemotherapy.

P. Philip, A. Zhu, M. Borad, 2016 .

Resected pancreatic adenocarcinoma: An Asian institution's experience

P. Chow, S. Choo, C. Chan, 2021, Cancer reports.

Targeted Therapy in Hepatocellular Carcinoma

S. Choo, C. Chua, 2011, International journal of hepatology.

Response to targeted therapy or chemotherapy following immunotherapy in patients with gastrointestinal cancers - a case series

S. Choo, C. Chee, Rayan Alsuwaigh, 2019, Journal of Immunotherapy for Cancer.

Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.

H. Huynh, K. Soo, H. Ong, 2012, Journal of hepatology.

A Phase 1 dose-finding and pharmacodynamic study of rapamycin in combination with bevacizumab in patients with unresectable hepatocellular carcinoma.

H. Huynh, C. Thng, S. Choo, 2013, European journal of cancer.

Comprehensive molecular characterization of mitochondrial genomes in human cancers

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2017, bioRxiv.

Author Correction: Pan-cancer analysis of whole genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2023, Nature.

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

M. Kudo, J. Bruix, A. Zhu, 2022, Journal of Experimental & Clinical Cancer Research.

Sex differences in oncogenic mutational processes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2019, Nature Communications.

Real‐world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center

S. Choo, S. Tan, K. Ng, 2020, Asia-Pacific journal of clinical oncology.

CD38 is a good predictor of anti-PD-1 immunotherapy responsiveness in hepatocellular carcinoma

P. Chow, E. Newell, S. Choo, 2019, bioRxiv.

Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

E. Felip, S. Choo, E. Garralda, 2023, ESMO open.

Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies

U. Dafni, E. Felip, J. Tabernero, 2021, ESMO open.

HER2 as a therapeutic target in gallbladder cancer—aye or nay?

B. Teh, S. Choo, J. Lam, 2016 .

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

S. Choo, S. Tan, K. Ng, 2021, Liver Cancer.

Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study—An Asian Tertiary Cancer Center Experience

N. Iyer, S. Choo, A. Takano, 2021, JCO precision oncology.

Novel Targets in Advanced Colorectal Cancer

S. Choo, C. Chua, J. Lee, 2018, Current Colorectal Cancer Reports.

89 The immune marker LAG-3 increases the predictive value of CD38+ immune cells for survival outcome in immunotherapy-treated hepatocellular carcinoma

S. Choo, J. Yeong, H. Toh, 2021, Journal for ImmunoTherapy of Cancer.

Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209-678): a single arm, single centre, phase 2 trial.

Jia Qi Lim, C. Thng, W. Zhai, 2021, The lancet. Gastroenterology & hepatology.

Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer

S. Choo, S. Ong, B. Chowbay, 2012, Cancer Chemotherapy and Pharmacology.

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

H. Huynh, K. Soo, E. Tran, 2008, Journal of cellular and molecular medicine.

A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

T. Yau, S. Choo, Jianming Xu, 2019, Therapeutic advances in medical oncology.

Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.

M. Kudo, A. Santoro, F. Costanzo, 2019, Journal of Clinical Oncology.

Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian center.

S. Choo, S. Tan, K. Ng, 2020 .

Deconvolution assessment of splenic and splanchnic contributions to portal venous blood flow in liver cirrhosis.

C. Thng, D. Koh, S. Choo, 2011, Medical physics.

National Cancer Centre Singapore Consensus Guidelines for Hepatocellular Carcinoma

C. Thng, P. Chow, S. Choo, 2016, Liver Cancer.

Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.

M. Kudo, T. Yau, A. El-Khoueiry, 2017 .

Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.

H. Huynh, K. Soo, A. Chung, 2011, Current cancer drug targets.

Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery

Sarah Ng, W. Burkholder, S. Choo, 2017, Scientific Reports.

Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series.

C. Thng, S. Choo, T. Hennedige, 2019, Immunotherapy.

Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study

M. Kudo, B. Sangro, T. Yau, 2018 .

A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.

R. Loberg, J. Tabernero, S. Choo, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore

S. Choo, W. Yong, L. Teo, 2022, Expert opinion on drug metabolism & toxicology.

The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma

P. Chow, S. Choo, P. Cheow, 2015, PloS one.

Do elderly patients benefit from enrollment in phase I clinical trials

S. Choo, E. Tan, D. Tan, 2013 .

Phase I/II Study of NC-6004, A Novel Micellar Formulation of Cisplatin, In Combination with Gemcitabine in Patients with Pancreatic Cancer in Asia - Results of Phase I

S. Choo, W. Su, Li‐Tzong Chen, 2012 .

Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study

M. Kudo, A. El-Khoueiry, B. Sangro, 2017 .

Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma.

H. Huynh, K. Soo, H. Koong, 2009, Current cancer drug targets.

Multicenter Phase II Study of Sequential Radioembolization-Sorafenib Therapy for Inoperable Hepatocellular Carcinoma

K. Soo, S. Choo, P. Chow, 2014, PloS one.

Hepatic artery infusion in the treatment of colorectal cancer metastases

S. Choo, A. Venook, 2008 .

Prospective study to determine early hypertrophy of the contra‐lateral liver lobe after unilobar, Yttrium‐90, selective internal radiation therapy in patients with hepatocellular carcinoma

S. Choo, C. Chan, J. Allen, 2018, Surgery.

Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer

S. Choo, C. Chua, I. Tan, 2015, Cancer Chemotherapy and Pharmacology.

Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma

S. Choo, T. Lim, M. Lau, 2023, Frontiers in Immunology.

Correction: The Singapore Liver Cancer Recurrence (SLICER) Score for Relapse Prediction in Patients with Surgically Resected Hepatocellular Carcinoma

P. Chow, S. Choo, P. Cheow, 2015, PloS one.

First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation

J. Llovet, S. Choo, T. Meyer, 2016 .

Gastric peritoneal carcinomatosis - a retrospective review

Khee Chee Soo, K. Soo, S. Choo, 2017, World journal of gastrointestinal oncology.

A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.

S. Choo, J. Allen, J. Chang, 2015, HPB.

Real-World Data on Clinical Outcomes of Patients with Liver Cancer: A Prospective Validation of the National Cancer Centre Singapore Consensus Guidelines for the Management of Hepatocellular Carcinoma

C. Thng, P. Chow, S. Choo, 2021, Liver Cancer.

Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets

R. Goldberg, H. Lenz, A. Shields, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II open-label, single-centre, non-randomized trial of Y90 transarterial radioembolization in combination with nivolumab in Asian patients with intermediate stage hepatocellular carcinoma: An immunological study of radioembolization in combination with anti-PD1 therapy in HCC.

C. Thng, P. Chow, W. Zhai, 2018 .

A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

H. Huynh, C. Thng, B. Goh, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

Nuno A. Fonseca, Benjamin J. Raphael, Allison P. Heath, 2020, Nature Communications.

Multimodal molecular landscape of response to Y90-resin microsphere radioembolization followed by nivolumab for advanced hepatocellular carcinoma

May Yin Lee, Jia Qi Lim, W. Tam, 2023, Journal for ImmunoTherapy of Cancer.

A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin (SECOX) in patients with advanced hepatocellular carcinoma: Final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study.

S. Fan, T. Yau, S. Choo, 2013 .

A phase I/II study of AZD6244 in combination with sorafenib in advanced hepatocellular carcinoma.

C. Thng, B. Goh, S. Choo, 2012 .

The evolving landscape of therapeutic drug development for hepatocellular carcinoma.

S. Choo, I. Tan, D. Chong, 2013, Contemporary clinical trials.

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

H. Huynh, K. Soo, H. Koong, 2009, Journal of cellular and molecular medicine.

Comparison of health state values derived from patients and individuals from the general population

Y. Cheung, S. Choo, N. Luo, 2017, Quality of Life Research.

S. Choo, S. Chan, F. Mo, 2022, Liver Cancer.

Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?

S. Choo, S. Tan, K. Ng, 2022, Asia-Pacific journal of clinical oncology.

Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040.

A. El-Khoueiry, S. Choo, J. Neely, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

47LBA Phase II trial of sorafenib with capecitabine and oxaliplatin (SECOX) in patients with locally advanced or metastatic hepatocellular carcinoma

S. Choo, J. Wong, R. Poon, 2009 .

A phase II open-label, single-center, nonrandomized trial of Y90-radioembolization in combination with nivolumab in Asian patients with advanced hepatocellular carcinoma: CA 209-678.

C. Thng, S. Choo, C. Chan, 2020, Journal of Clinical Oncology.